Westbrook Comprehensive Cancer Institute · Cambridge, Massachusetts 415 Main St · Cambridge, MA 02142
Westbrook Comprehensive Cancer Institute
Research

Scientific programs built to deepen understanding of cancer.

Our research portfolio moves across discovery biology, disease-specific investigation, translational science, biomarkers, precision medicine, and cancer control.

Blood Cancer Research

Concentrated expertise in hematologic malignancies.

Blood cancers offer a powerful setting for studying cancer biology, immune interactions, clonal evolution, treatment resistance, and measurable disease response.

LEUKEMIA

Leukemia Research

Investigating molecular drivers, clonal evolution, measurable disease, treatment response, and mechanisms of resistance across acute and chronic leukemias.

LYMPHOMA

Lymphoma Research

Studying lymphoma biology, tumor-immune interactions, molecular subtypes, biomarkers, and therapeutic strategies.

MULTIPLE MYELOMA

Myeloma Research

Researching disease progression, marrow biology, treatment resistance, and approaches to durable disease control.

MARROW DISORDERS

Blood & Marrow Disorders

Investigating malignant and pre-malignant hematologic conditions and the biological pathways that connect disease states.

Additional Research Areas

Cross-cutting science strengthens every program.

Genomics & Molecular Profiling

Characterizing genomic alterations and molecular signatures associated with disease biology and treatment response.

Immunology & Cell Therapy

Exploring immune-cell function, cellular therapies, and mechanisms that influence anti-cancer activity.

Biomarkers & Precision Medicine

Developing measurable indicators that can improve classification, monitoring, and response-guided research.

Tumor Microenvironment

Understanding how surrounding cells, signals, and tissue architecture influence cancer behavior.

Drug Resistance

Studying why cancers adapt to treatment and identifying research opportunities to overcome resistance.

Prevention & Cancer Control

Examining risk, screening, early detection, survivorship, and strategies that reduce cancer burden.